Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

Leukemia Research

Volumn 36, Issue 4, 2012, Pages 397-400

  Itzykson, R ^a   Thepot S ^a   Beyne Rauzy, O ^b   Ame, S ^c   Isnard, F ^d   Dreyfus, F ^e   Salanoubat, C ^f   Taksin, A L ^g   Chelgoum, Y ^h   Berthon, C ⁱ   Malfuson, J V ^j   Legros, L ^k   Vey, N ^l   Turlure, P ^m   Gardin, C ^a   Boehrer, S ^a   Ades, L ^a   Fenaux, P ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e AP HP and Paris 5 University ^*  (France)

^f Centre Hospitalier du Sud Francilien   (France)

^g CENTRE HOSPITALIER DE VERSAILLES   (France)

^h EDOUARD HERRIOT HOSPITAL   (France)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j PERCY MILITARY HOSPITAL   (France)

^k UNIVERSITY HOSPITAL OF NICE   (France)

^l INSTITUT PAOLI CALMETTES   (France)

^m Centre Hospitalier Universitaire Limoges   (France)

more..

Author keywords

Erythropoiesis stimulating agents; Hypomethylating agents; Myelodysplastic syndromes

Indexed keywords

ANTIANEMIC AGENT; AZACITIDINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG RESPONSE; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; COHORT STUDIES; FEMALE; HEMATINICS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84857238272     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.11.019     Document Type: Article

References (13)

1. Cheson B.D., Bennett J.M., Kantarjian H., Pinto A., Schiffer C.A., Nimer S.D., et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000, 96(12):3671-3674.
2. Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108(2):419-425.
3. Hellstrom-Lindberg E., Gulbrandsen N., Lindberg G., Ahlgren T., Dahl I.M., Dybedal I., et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003, 120(6):1037-1046.
4. Jadersten M., Malcovati L., Dybedal I., Della Porta M.G., Invernizzi R., Montgomery S.M., et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008, 26(21):3607-3613.
5. Jadersten M., Montgomery S.M., Dybedal I., Porwit-MacDonald A., Hellstrom-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 2005, 106(3):803-811.
6. Park S., Grabar S., Kelaidi C., Beyne-Rauzy O., Picard F., Bardet V., et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008, 111(2):574-582.
7. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10(3):223-232.
8. Boehrer S., Beyne-Rauzy O., Prebet T., Park S., Guerci A., Stamatoulas A., et al. Interim results of a randomized phase II trial of azacitidine (AZA) +/- EPO in lower risk myelodysplastic syndrome (MDS) resistant to an erythropoietic stimulating agent (ESA) alone. Blood (ASH Annual Meeting Abstracts) 2010, 116:1880.
9. Itzykson R., Thepot S., Quesnel B., Dreyfus F., Beyne-Rauzy O., Turlure P., et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011, 117(2):403-411.
10. Hellstrom-Lindberg E., Malcovati L. Supportive care, growth factors, and new therapies in myelodysplastic syndromes. Blood Rev 2008, 22(2):75-91.
11. List A.F., Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Gore S., Bennett J.M., et al. Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission. ASCO Annual Meeting Abstracts 2008, p. 7006.
12. Arcasoy M.O. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008, 141(1):14-31.
13. Rizzo J.D., Brouwers M., Hurley P., Seidenfeld J., Arcasoy M.O., Spivak J.L., et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 2010, 116(20):4045-4059.